Company* (Country, Symbol) | Company* (Country, Symbol) | Type/Product Area | Terms/Details (Date) |
3-Dimensional Pharmaceuticals Inc. (DDDP) | Centocor Inc. (subsidiary of Johnson & Johnson; NYSE:JNJ) | Agreement for worldwide rights to 3DP's orally active direct thrombin inhibitor program, 3DP-4815 | 3DP will receive an up-front cash payment of $6M and further payments of up to $44M based on milestones; Centocor will be responsible for development and worldwide commercialization (1/2) |
Abgenix Inc. (ABGX) | Amgen Inc. (AMGN) | Extended research collaboration calling for Abgenix to use its Xeno-Mouse technology to generate fully human monoclonal antibodies to antigen targets provided by Amgen over the five-year term | Original agreement began in April 1999 (1/9) |
Abgenix Inc. (ABGX) | Celltech Group plc (UK; NYSE:CLL) | Licensing agreement for SLAM (Selected Lymphocyte Antibody Method) technology | Abgenix will receive a $17M up-front payment in the form of Celltech stock, plus royalties; Celltech will use the technology to identify proteins as drug discovery targets (2/6) |
Affymetrix Inc. (AFFX) | Genomic Solutions Inc. (GNSL) | License agreement for commercialization rights for low- and medium-density DNA arrays | Genomic Solutions gained a nonexclusive, worldwide, royalty-bearing license; Affymetrix will receive undisclosed fees and royalty payments on arrays sold (1/4) |
Affymetrix Inc. (AFFX) | Lexicon Genetics Inc. (LEXG) | BiotechAccess agreement giving Lexicon broad access to Affymetrix's GeneChip arrays, instrumentation and software | Lexicon will use the technology in its genomics research and development activities, as well as to share phenotypic and expression analysis information on new and existing targets (1/11) |
Altus Biologics Inc.* | Triangle Pharmaceuticals Inc. (VIRS) | Research agreement to develop biocatalytic processes for use in the synthesis of compounds in Triangle's drug development pipeline | Altus will receive funding, in return for specific worldwide commercialization rights (1/29) |
Ambion Inc.* | Qiagen Inc. (the Netherlands; QGENF) | Collaboration granting Qiagen nonexclusive worldwide rights to Ambion's RNAlater RNA stabilization technology | Financial terms were not disclosed (2/14) |
Applied Biosystems Group (NYSE:ABI) | Agilent Technologies Inc. (NYSE:A) | Technology access agreement for Agilent to supply custom in situ-synthesized oligonucleotide microarrays to Applied Biosystems | The agreement does not cover commercialization of the Agilent microarrays (1/24) |
Arakis Ltd. (UK)* | KS Biomedix Holdings plc (UK; LSE:KSB) | Collaboration to develop new arthritis treatments | The collaboration will focus on AD 452 and KSB306/7 (3/7) |
Ashni Naturaceuticals Inc.* | Silico Insights Inc.* | Collaboration to apply informatics techniques to identify regulatory and post-translational pathways from genomics and proteomics data | Ashni will use its BIOPrinting technology and Silico will apply its informatics platform in the collaboration (3/14) |
atugen AG (Germany)* | G.O.T. Therapeutics GmbH (Germany)* | Collaboration to develop new lipid formulations for enhanced intra-cellular delivery of atugen's GeneBloc molecules | The companies will share all costs and intellectual property equally; G.O.T. will retain exclusive use of resultant products in DNA therapy, and atugen will retain all other rights related to target discovery, validation and therapeutic use (2/26) |
Aurora Biosciences Corp. (ABSC) | Allergan Inc. (NYSE:AGN) | Agreement for ion channel drug discovery for ophthalmic indications | Includes an up-front payment to Aurora and additional milestone payments and royalties (1/9) |
Aurora Biosciences Corp. (ABSC) | Deltagen Inc. (DGEN) | Nonexclusive license agreement for Aurora's green fluorescent protein technology | Deltagen received nonexclusive rights to use the technology in transgenic organisms, including knockout mice, within the U.S.; Deltagen will make certain license fee payments to Aurora and has the option to expand its use of the technology into other territories upon additional payments to Aurora (1/24) |
Avalon Pharmaceuticals Inc.* | ImmunoGen Inc. (IMGN) | License agreement to develop antibody-based products based on genomic targets | Avalon will receive milestone payments; agreement is focused on cancer and the goal is to get three new targets into ImmunoGen's pipeline every year (1/25) |
Bavarian Nordic Research Institute A/S (Denmark)* | Vaccine Solutions Pty. (Australia)* | License agreement for the right to sublicense, develop, produce, manufacture and market HIV vaccines incorporating Vaccine Solutions' Polytope technology | Bavarian pays up-front, milestone and royalty payments and has an option to license the technology for four other vaccines (1/29) |
Bioniche Life Sciences Inc. (Canada; TSE:BNC) | UroCor Inc. (UCOR) | Strategic alliance seeking the development and approval for Cystistat | UroCor will have exclusive rights to market and distribute Cystistat; the agreement also provides UroCor with an option to market Bioniche's mycobacterial cell wall-DNA complex for bladder and prostate cancer in the U.S.; UroCor paid Bioniche an up-front payment of $750,000, and UroCor will pay additional payments totaling $2.28M for reaching milestones (3/8) |
Biovation Ltd. (UK; unit of Merck Group)* | Epicyte Pharmaceutical Inc.* | Research agreement to optimize antibodies for development through Epicyte's Plantibody technology by applying Biovation's Biodisplay and DeImmunization technologies to the antibody optimization | Biovation will earn research revenues, milestones and royalties (2/7) |
Boston Probes Inc.* | Gene Therapy Systems Inc.* | Five-year, nonexclusive license for the sale of GeneGrip life science research products that incorporate PNA technology | Gene Therapy will pay Boston Probes an up-front fee, minimum annual royalties, as well as earned royalties from product sales (2/12) |
Caliper Technologies Inc. (CALP) | Structural GenomiX* | Joint development collaboration focused on high-throughput protein analysis with Caliper's Automated Microfluidics System 90 platform | Financial terms were not disclosed (1/8) |
Celera Genomics Inc. (NYSE:CRA) | Genset SA (France; GENXY) | Multiyear subscription agreement granting Genset access to Celera's databases | Financial terms were not disclosed (1/10) |
Celera Genomics Inc. (NYSE:CRA) | Vita Genomics (Taiwan)* | Multiyear subscription agreement granting Vita's researchers access to the Celera Discovery System to use Celera's integrated database products, bioinformatics systems and other discovery tools | Financial terms were not disclosed (3/19) |
CeNeS Pharmaceuticals plc (UK; LSE:CEN) | Cangene Corp. (Canada; TSE:CNJ) | Agreement to develop a slow-release formulation of an unnamed protein drug for Cangene | CeNeS will apply its Depocore technology to reduce 30-fold the frequency with which the Cangene drug must be injected; CeNeS receives an initial fee, will manufacture the product and will receive royalties (2/14**) |
Cerep SA (France; Neuer Markt:CEREP) | Laboratoires Fournier SA (France)*, Grunenthal (Germany)*, Zambon Group SpA (Italy)* and a fourth unnamed company | Collaboration agreements for the creation of libraries of therapeutic compounds | The agreements are for two years each; each library will be paid for separately with the four companies paying equal amounts (1/24**) |
Chiron Corp. (CHIR) | Zarix Inc.* | Agreement giving Zarix exclusive worldwide rights to recombinant human macrophage-colony stimulating factor to treat cancer and infectious disease | Zarix gains the rights to make, develop and commercialize rM-CSF while shouldering development costs; Chiron will receive up-front license fees, milestone payments and royalties (2/1) |
Chiron Corp. (CHIR) | AcroMetrix Inc.* | Agreement giving AcroMetrix a worldwide, semi-exclusive license, including blood screening, allowing it to research, develop, manufacture and sell HCV and HIV nucleic acid probe quality controls, standards and quantification panels for in vivo diagnostics | Chiron will receive an up-front license fee, milestone payments and royalties on sales (2/1) |
Cognia Corp.* | Biobase GmbH (Germany)* and Harvard Medical School | Alliance granting researchers access to bioinformatics products | No further details were disclosed (2/8) |
Commonwealth Biotechnologies Inc. (CBTE) | november AG (Germany; Neuer Markt: NBX) | Research and development joint venture agreement using november's electrohybridization technology | The companies will use the technology to develop new methods for the detection of microbial contamination in a variety of areas, including water and soil (2/9) |
COR Therapeutics Inc. (CORR) and Schering-Plough Corp. (NYSE:SGP) | Genentech Inc. (NYSE:DNA) | Copromotion agreement for Integrilin | Genentech will copromote Integrilin and COR and Schering will copromote TNKase and Activase (1/8) |
Crucell NV (the Netherlands; CRXL) | Cell Genesys Inc. (CEGE) | Licensing agreement for access to PER.C6 technology | Cell Genesys will license Crucell's PER.C6 adenoviral packaging cell line for research purposes, with an option to convert to a commercial license within five years (1/15) |
Crucell NV (the Netherlands; CRXL) | DirectGene Inc.* | Production agreement to manufacture clinical-grade batches of DirectGene's product to treat prostate cancer using its human cell line production platform | The production agreement follows a licensing agreement in 2000 for DirectGene's access to Crucell's PER.C6 technology (2/1) |
Cubist Pharmaceuticals Inc. (CBST) | Gilead Sciences Inc. (GILD) | Licensing agreement to market Cidecin and an oral formulation of daptomycin overseas | The deal worth $44M includes an up-front licensing fee of $13M for Cubist, as well as additional payments of up to $31M in milestones, plus royalties (1/8) |
Curis Inc. (CRIS) | Aegera Therapeutics Inc.* | Licensing and research agreement granting Curis exclusive worldwide rights to skin-derived adult stem cell technologies | The deal is valued at more than $25M (1/8) |
DoubleTwist Inc.* | Genomatix Software GmbH (Germany)* | Partnership aimed at aiding scientific gene characterization | The collaboration will merge DoubleTwist's Annotated Human Genome Database with Genomatix's Promoter Resource database (1/23) |
DNA Sciences Inc.* | Amersham Pharmacia Biotech Inc. (unit of Nycomed Amersham plc; LSE:NAM; NYSE:NYE) | Collaboration to develop microchannel chip technology for the automated, high-throughput analysis of nucleic acids | The companies will combine their expertise and intellectual property in microfabrication, engineering, reagent and applications development, and production scale sample processing to develop a robust high-throughput system to be marketed by AP-Biotech; DNA Sciences will be paid licensing fees and royalties (1/18) |
Dyax Corp. (DYAX) | Human Genome Sciences Inc. (HGSI) | Exclusive licensing agreement to purify HGS's B-lymphocyte stimulator protein, BLyS | HGS received a protein purification license to a family of Dyax's custom peptide ligands; Dyax received a license fee and will receive commercial milestone payments, as well as royalties (1/8) |
Dyax Corp. (DYAX) | Abgenix Inc. (ABGX) | Collaboration to develop new technologies for discovering and developing human antibody therapeutics | Companies will share costs and each will pay reciprocal commercialization fees (1/8) |
EraGen Biosciences Inc.* | Genome Therapeutics Corp. (GENE) | Product development and marketing collaboration to deliver EraGen's MasterCatalog with Genome Therapeutics' Pathogenome | The companies hope to expand discovery potential by combining the two products (3/5) |
Gene Logic Inc. (GLGC) | IDEC Pharmaceuticals Inc. (IDPH) | Agreement granting IDEC a subscription to the Gene Express Oncology Data Suite for use in drug discovery | Financial details were not disclosed (1/8) |
Gene Logic Inc. (GLGC) | Genentech Inc. (NYSE: DNA) | Subscription agreement for the BioExpress Module of Gene Logic's GeneExpress Suite for use in its drug discovery and development programs | Financial terms of the multiyear subscription were not disclosed (2/15) |
Genetix Group plc (UK: LSE:GTX) | Pall Corp. (NYSE:PLL) | Strategic alliance to develop and commercialize novel membranes | Membranes will optimize robotic high-density array printing and detections methods for DNA and proteins (2/26) |
GeneTrace Systems Inc.* | Molecular Mining Corp. (Canada)* | Collaboration to design, analyze, define and validate a physiological network model for application in drug discovery | Companies will co-fund the research and share the revenues generated by any findings (1/18) |
Genicon Sciences Corp.* | Pall Corp. (NYSE:PLL) | Agreement to apply Pall's membrane technology and Genicon's RLS technology to develop an enhanced system for the labeling, detection and study of biological analytes | Terms of the agreement were not disclosed (2/27) |
Genometrix Inc.* | VistaGen Inc.* | Collaboration to combine in vitro stem cell biology with high-throughput microarrays to discover surrogate markers for predictive toxicology screening for drug development | Collaboration will focus on identifying drug-responsive genes (1/10) |
Genomics Collaborative Inc.* | NetGenics Inc.* | Joint development collaboration to create and develop the first application of the genotypic DataMart | Companies will apply the DataMart to the analysis and mining of annotated, genotypic data (1/9) |
Genta Inc. (GNTA) | atugen AG (Germany)* | Licensing agreement granting access to antisense patents | Nonexclusive license agreement includes an up-front cash payment, yearly cash maintenance payments and royalties on sales (1/29) |
Genzyme Transgenics Corp. (GZTC) | Atlantic BioPharmaceuticals Inc.* | Agreement to produce Atlantic's recombinant human protein, ABI.001 | Genzyme will produce transgenic goats that express the protein in their milk; ABI.001 is under investigation to treat myasthenia gravis, an autoimmune disorder (2/14) |
Genzyme Transgenic Corp. (GZTC) | Centocor Inc. (subsidiary of Johnson & Johnson; NYSE:JNJ) | Expanded agreement to include a worldwide semi-exclusive license for commercial production of tumor necrosis factor antagonists | Agreement calls for a license fee payment to Genzyme of $4M (1/8) |
Gryphon Sciences Inc.* | Geneva Proteomics Inc.* | Collaboration for the chemical synthesis of proteins identified by proteomic analysis of chosen biological fluids, cells and tissues in healthy and sick individuals | Geneva Proteomics will use its technologies to identify proteins and will make small amounts of the proteins using Gryphon's chemical synthesis technology (2/5) |
Heska Corp. (HSKA) | Genzyme Corp. (GENZ) | Agreement for marketing rights for a product for the detection of Giardia and Cryptosporidium | The agreement gives Heska the right to market the product for use in dogs and cats (3/7) |
HTS Biosystems Inc.* | Dyax Corp. (DYAX) | Nonexclusive license exchange agreement for premarket access to HTS's grating-coupled surface plasmon resonance array system | Dyax will grant HTS a patent license to use its phage display technology for the generation of antibody chip products for the HTS system, for which Dyax would receive royalties on sales (2/12) |
Icogen Corp.* | HemeBiotech A/S (Sweden)* | Agreement to develop a cell-based system to produce a therapeutic protein | No further details were disclosed (1/17) |
Idun Pharmaceuticals Inc.* | Selective Genetics Inc.* | License agreement for the use of Idun's Bcl-2 gene | Selective will use the gene in conjunction with its delivery technologies to develop gene therapy products for tissue repair and regeneration (2/27) |
ILEX Oncology Inc. (ILXO) | Bioenvision Inc. (UK; OTC BB:BIOV) | Agreement to co-develop clofarabine | ILEX will develop clofarabine in the U.S. and and Canada, where it will have exclusive manufacturing and marketing rights; Bioenvision will maintain exclusive marketing and manufacturing rights outside North America; ILEX will pay $1.1M in an up-front licensing fee and make milestone and royalty payments (3/15) |
Imgenex Corp.* | Genzyme Molecular Oncology (GZMO) | Alliance aimed at reagent development useful in the study of angiogenesis | Imgenex will develop moncolonal antibodies that recognize and potentially will interfere with the function of proteins discovered by the companies; Imgenex will retain commercialization rights and will pay royalties to Genzyme (2/5) |
ImmunoGen Inc. (IMGN) | Millennium Pharmaceuticals Inc. (MLNM) | Five-year agreement for ImmunoGen's Tumor-Activated Prodrug method of delivering cytotoxic agents | Millennium is paying $2M up front and potentially $40M more in milestone payments; it gains an option for exclusive product licenses in return for a restricted, undisclosed number of antigen targets (3/6) |
Incyte Genomics Inc. (INCY) | Agilent Technologies Inc. (NYSE:A) | Licensing agreement for development and commercialization of gene expression arrays | Agilent gains access to Incyte cDNA clones to develop human and animal microarrays (1/8) |
Incyte Genomics Inc. (INCY) | Genicon Sciences Corp.* | Development agreement for the detection of infinitesimal levels of proteins present in biological samples | Incyte will receive certain rights to codevelop and commercialize Genicon's RLS Technology with Incyte array products (2/15) |
Incyte Genomics Inc. (INCY) | Oxagen Ltd. (UK)* | Collaborative research agreement to investigate the genetics of osteoporosis | Program will test for genetic association between key candidate genes and bone mineral density, fracture and other osteoporosis-related phenotypes; Oxagen will have access to the full LifeSeq Gold database for use in all of its other disease areas (1/29) |
Incyte Genomics Inc. (INCY) | Senomyx Inc.* | Licensing agreement for Incyte's gene sequence database to discover genes involved in taste, olfaction and the detection of pheromones | Under specific situations Senomyx will have the ability to take exclusive licenses to gene patents that relate to commercialization of flavor and fragrance products (1/5) |
Infimed Therapeutics Inc.* | Praecis Pharmaceuticals Inc. (PRCS) | Collaboration for drug delivery technologies | InfiMed will apply its Improved Formulation Entity platform for sustained release of protein- and peptide-based drugs to an undisclosed Praecis peptide (1/4) |
Inflazyme Pharmaceuticals Ltd. (TSE:IZP) | Helicon Therapeutics Inc.* | Research agreement to examine the potential of small-molecule anti-inflammatory compounds in the learning and memory fields | Helicon will evaluate compounds and has the right to license a compound for development upon making a milestone payment to Inflazyme; Helicon will be responsible for all preclinical costs and Inflazyme will receive royalties on sales (2/7) |
InforMax Inc. (INMX) | Biomax Informatics AG (Germany) | Agreement granting InforMax exclusive worldwide distribution rights to the BioRS Integration and Retrieval System developed by Biomax | As part of the four-year agreement, the companies will integrate BioRS's capabilities with the InforMax platform, and InforMax's sales force will market solutions using the combined technologies (1/16) |
Integrative Proteomics Inc. | Bruker AKS Inc.*, Bruker Daltonics Inc. (BDAL) and Bruker Instruments Inc.* (members of Bruker BioSpin Group) | Stragetic alliance focused on multidisciplinary proteomics technologies based on protein X-ray crystallography, biological NMR and mass spectrometry | Each of the Bruker companies agreed to make an undisclosed equity investment in IPI (3/12) |
IntraBiotics Pharmaceuticals Inc. (IBPI) | Albany Molecular Research Inc. (AMRI) | Research and technology licensing agreement for the discovery and development of anti-infective therapies | Agreement is for two years and is renewable; AMRI will receive technology access fees, research funding and milestone payments, as well as royalties; IntraBiotics gains an exclusive worldwide license to commercialize and develop resulting drugs (2/1) |
IntraBiotics Pharmaceuticals Inc. (IBPI) | Diversa Corp. (DVSA) | Agreement to identify and develop small-molecule compounds with antibacterial or antifungal properties derived from Diversa's libraries | Diversa gets access fees, research fees and milestone payments; IntraBiotics gets an exclusive worldwide license to resulting products; deal is worth $20M (1/9) |
Introgen Therapeutics Inc. (INGN) | Selective Genetics Inc.* | Agreement for process and formulation development to supply Selective with clinical-grade manufacturing services for Selective's soft tissue repair gene therapy programs | Further details were not disclosed (3/8) |
KS Biomedix Holding plc (UK; LSE:KSB) | Aurelium BioPharma Inc. (Canada)* | Research and development collaboration that calls for KS to develop super-high-affinity antibodies for Aurelium protein targets expressed on tumor cells that are resistant to a wide range of anticancer drugs | The companies initially will focus on blood cancers (2/20) |
Large Scale Biology Corp. (LSBC) | Biosite Diagnostics Inc. (BSTE) | Technology alliance to generate the antibody and protein target components required to produce the first generation of commercial protein chips | Large Scale's proteomics subsidiary will provide 2,000 to 5,000 protein targets from its programs, as well as expressed proteins produced with its Geneware technology; Biosite will use its high-throughput Omniclonal phage display technology to generate high-affinity antibodies to the targets (1/30) |
Large Scale Biology Corp. (LSBC) | ProdiGene Inc.* | Collaboration on the development and large-scale manufacture of therapeutic antibodies | Collaboration will use Large Scale's manufacturing facility in Owensboro, Ky.; it will focus on the commercialization of proteins produced in plants (2/6) |
Lexicon Genetics Inc. (LEXG) | Abgenix Inc. (ABGX) | Multiyear agreement under which Lexicon will validate monoclonal antibody targets for Abgenix | Lexicon will use its mammalian assays to determine a gene sequence's function in a mammalian system (1/3) |
Lexicon Genetics Inc. (LEXG) | Immunex Corp. (IMNX) | Multiyear, nonexclusive sublicense to use gene targeting technology for Immunex's internal research programs | Lexicon will receive annual license fees, technology usage fees and milestone payments (2/6) |
Lynx Therapeutics Inc. (LYNX) | Celera Genomics Inc. (NYSE:CRA) | Agreement to integrate sets of Lynx's gene expression data into the Celera Discovery System and an agreement in which Lynx will apply its MPSS technology to perform additional gene expression analyses for Celera | Financial terms were not disclosed (3/8) |
Lynx Therapeutics Inc. (LYNX) | Phytera Inc.* | Collaboration to identify genes from plants involved in the biosynthesis of anti-oxidant polyphenols | Lynx and Phytera intend to validate gene targets and jointly commercialize the genes with other partners (1/30) |
MDS Proteomics (spin-out of MDS Inc.; Canada; NYSE:MDZ) | IBM (IBM) | Strategic alliance to establish a public research database of protein analyses and to conduct research projects | IBM will be the preferred supplier of hardware, software and services and will make an equity investment in MDS; the alliance will target understanding the interactions among proteins that trigger chemical reactions in cells and cause diseases such as cancer, AIDS and depression (1/30) |
Medarex Inc. (MEDX) | Biosite Diagnostics Inc. (BSTE) and Eos Biotechnology Inc.* | Collaboration to use Eos targets to create anticancer antibodies using Medarex and Biosite's Transphage Technology | Eos will provide Biosite with tens of targets over three years, development fees, milestone fees, royalties and maintenance fees; Biosite will get diagnostic rights to the targets and Medarex expects to receive payment pursuant to its existing 1999 collaboration with Eos for antibody generation of Eos anticancer targets (2/26) |
Medarex Inc. (MEDX) | B. Twelve Inc.* | Research, development and commercialization agreement for cancer therapeutics using Medarex's UltiMAb Human Antibody Development System and B. Twelve's targeted technology | B. Twelve will develop and commercialize resulting products; Medarex expects to receive license fees and milestone payments, as well as royalties on potential sales; Medarex also received 9% of B. Twelve's outstanding shares (1/22) |
Medarex Inc. (MEDX) | Immusol Inc.* | Strategic alliance for the development of fully human antibody therapeutics | The agreement calls for equal cost-sharing responsibilities for development and commercialization of potential therapeutics developed by applying Medarex's UltiMAb Human Antibody Development System to Immusol targets (2/20) |
Medarex Inc. (MEDX) | Seattle Genetics Inc.* | Strategic alliance to use Medarex's UltiMAb Human Antibody Development System to jointly develop and commercialize monoclonal antibody-based anticancer therapeutics | The companies will share development costs and jointly commercialize any resulting products; Medarex will purchase $2M of Seattle Genetics' stock concurrent with its proposed initial public offering (2/7) |
MedImmune Inc. (MEDI) | Targesome Inc.* | Agreement to study the potential of combining Vitaxin with Targesome's nanoparticle technology | MedImmune made a $1.5M equity investment in Targesome and has agreed to make milestone payments and future royalties on resulting products (2/23) |
Micralyne Inc. (Canada)* | MDS Sciex (Canada; division of MDS Inc.; TSE: MDS; NYSE:MDZ) | Multiyear agreement to jointly develop microfluidic technology for use in drug discovery instrumentation | Micralyne will license existing microfluidic technology and develop new technology for use in frontal affinity chromatography (1/25) |
Millennium Pharmaceuticals Inc. (MLNM) | Protein Design Labs Inc. (PDLI) | Agreement giving Millennium options to take commercial licenses for humanized antibodies | Agreement calls for Millennium to make an undisclosed signing fee and pay royalties on net sales of resulting monoclonal antibody products; Millennium can acquire licenses for up to three products for five years (3/13) |
Morphochem AG (Germany)* | Sosei Co. Ltd. (Japan)* | Collaborative research agreement to optimize an anticancer agent | Morphochem will produce libraries of small molecules; the companies will share intellectual property rights resulting from the collaboration (3/14) |
MorphoSys AG (Germany; Neuer Markt:MOR) | Biogen Inc. (BGEN) | Collaboration to apply MorphoSys' Human Combinatorial Antibody Library antibody-generation technology for expressed sequence tags to efforts to validate drug products | Biogen receives an option to develop selected antibodies identified through the collaboration, and will pay research costs and an undisclosed up-front technology access fee, as well as milestone payments and royalties (1/2) |
MorphoSys AG (Germany; Neuer Markt:MOR) | Centocor Inc. (subsidiary of Johnson & Johnson; NYSE:JNJ) | Technology license agreement granting Centocor access to MorphoSys' HuCAL technology for antibody generation | Deal is worth EUR22M (US$20.71M), calling for EUR19M in technology license fees and a EUR3M up-front payment to MorphoSys, which also will receive royalty payments on any commercialized drugs (1/3) |
MWG Biotech AG (Germany; DAX:NWU) | Affymetrix Inc. (AFFX) | Modified distribution agreement for the sale of Affymetrix's spotted array instrumentation in Europe and North and South America | MWG Biotech will offer the instrumentation in combination with its existing array and reagent product offerings; Affymetrix will continue to provide both the GeneChip and spotted array systems (2/1) |
Novazyme Pharmaceuticals Inc.* | Neose Technologies Inc. (NTEC) | Restructured collaboration agreement in which Neose relinquishes its joint venture right for Novazyme's enzyme replacement therapy for Pompe disease | Neose instead will receive royalty interest for each of Novazyme's drug candidates for lysosomal storage diseases; Neose also will receive cash payments and additional equity in Novazyme (3/1) |
november AG (Germany; Neuer Markt:NBX) | ACGT ProGenomics AG (Germany)* | Exclusive worldwide rights agreement to a new transfection system that transports nucleic acids into cells | The transfection system is based on a protein called TmHU of a hyperthermophilic bacterium; ACGT will receive royalties on TmHU sales (3/14**) |
Onyx Pharmaceuticals Inc. (ONXX) | XOMA LLC (XOMA) | Development and manufacturing agreement for CI-1042 | Onyx will provide XOMA with an up-front payment, support for development efforts, as well as milestone payments in the agreement worth $35M (1/29) |
Orchid BioSciences Inc. (ORCH) | Exelixis Inc. (EXEL) | Collaboration for access to Orchid's SNP code | Financial terms were not disclosed (1/10) |
OSI Pharmaceuticals Inc. (OSIP) | Genentech Inc. (NYSE:DNA) and Roche Holdings Inc. | Agreement to co-develop and commercialize OSI-774 for cancer | Roche and Genentech each will buy $35M worth of OSI stock along with paying up-front fees; agreement is potentially worth $187M (1/8) |
Oxagen Ltd. (UK)* | Amersham Pharmacia Biotech Ltd.* | Agreement for the SniPer high-throughput single nucleotide polymorphism genotyping technology platform | Oxagen has acquired access to SniPer for a minimum of three years (1/22) |
Paradigm Genetics Inc. (PDGM) | Rosetta Inpharmatics Inc. (RSTA) and Agilent Technologies Inc. (NYSE:A) | Licensing agreement for the Rosetta Resolver Expression Data Analysis System | Financial terms were not disclosed (12/29) |
Peregrine Pharmaceuticals Inc. (PPHM) | SuperGen Inc. (SUPG) | Vascular Targeting Agent technology licensing agreement | SuperGen will make an up-front equity investment in and make milestone payments to Peregrine that could total $8M, in addition to royalties (2/13) |
Pharmagene plc (UK; LSE:PGN) | WITA Proteomics AG (Germany)* | Collaboration to jointly identify, validate and develop drug targets for partners | Financial details were not disclosed (3/13) |
Phogen Ltd. (UK; joint venture between the Marie Curie Cancer Care charity and Cantab Pharmaceuticals plc; LSE:CTB; CNTBY) | atugen AG (Germany)* | Research collaboration to evaluate Phogen's VP22 Vectosome technology for the intracellular delivery of atugen's GeneBloc molecules, for applications in the field of functional genomics | atugen will use the technology to deliver its oligonucleotide-based GeneBlocs into cells; atugen will have an option to take a license to VP22 for use in target validation screens (1/17) |
PPD Discovery (subsidiary of PPD Inc.; PPDI) | Affymetrix Inc. (AFFX) | BiotechAccess agreement | PPD Discovery gains broad access to Gene-Chip arrays, instrumentation and software to monitor gene expression for use in genetics and genomics research and development activities (1/31) |
PPD Discovery (subsidiary of PPD Inc.; PPDI) | InforMax Inc.* | Technology access agreement for the GenoMax enterprise bioinformatics system | PPD Discovery gains broad access to the system to manage and analyze genomic data resulting from its functional genomics research program (2/28) |
Protogene Laboratories Inc.* | Sequenom Inc. (SQNM) | Collaborative agreement aimed at developing single nucleotide polymorphism analysis tools suitable for use with Sequenom's MassArray system in genomics research and diagnostics | The collaboration will integrate DNA microarray technology developed by Protogene with Sequenom's MassArray system to enhance high-throughput SNP analysis on a silicon chip format (1/26) |
Pyrosequencing AB (Sweden; SSE:PYRO) | Mosaic Technologies Inc.* | Cross-license agreement providing access to each other's DNA sequencing technologies | Pyrosequencing gains co-exclusive rights to Mosaic's fluorescent detection technology and Mosaic receives access to Pyrosequencing's sequencing by synthesis technology (3/20) |
Qiagen Genomics Inc. (QGENF) | Agilent Technologies Inc. (NYSE:A) | Reseller and copromotion agreement for companies to develop SNP genotyping systems | Qiagen will market the systems; companies will jointly develop Masscode tag chemistry and mass spectrometry instrumentation solutions for SNP discovery (1/10) |
Qiagen Genomics Inc. (QGENF) | Genomics Collaborative Inc.* | Collaboration to analyze genetic profiles | Analysis will be of profiles of geographically distinct patient populations with known poor drug metabolism vs. an equal set of control patients (1/8) |
Questcor Pharmaceuticals Inc. (AMEX:QSC) | Tularik Inc. (TLRK) | Licensing agreement for certain antifungal drug research technology | Tularik will make a cash payment and future milestone and royalty payments (2/15) |
Ricerca LLC* | ICOS Corp. (ICOS) | Agreement to produce a small-molecule inhibitor | No further details were disclosed (3/9) |
Rosetta Inpharmatics Inc. (RSTA) | Immunex Corp. (IMNX) | Licensing agreement for the Rosetta Revolver Expression Data Analysis System | Immunex licensed the Rosetta analysis system; no further details were disclosed (2/26) |
Scios Inc. (SCIO) | Quintiles Transnational Corp. (QTRN) | Commercialization agreement for Natrecor (nesiritide) to treat congestive heart failure | Quintiles will pay $35M for the commercialization of Natrecor through its corporate ventures group, PharmaBio Development; Quintiles subsidiary Innovex Inc. will provide a 180-person sales force for which Quintiles expects about a $100M consideration through a net sales royalty stream over the three-and-a-half year agreement (1/11) |
Structural Bioinformatics Inc.* | ArQule Inc. (ARQL) | Subscription agreement for SBI's ProMax 3-D drug target protein database | ArQule gains access to the database; financial details were not disclosed (3/8) |
SYN X Pharma Inc. (Canada; CDNX:SYY) | genOway SA (France)* | Collaboration to combine expertise in proteomics and genomics to develop cardiovascular and central nervous system drug targets | The companies will test products through Phase I trials and will then license the products to pharmaceutical companies (2/21) |
The Generics Group (UK; LSE: GEN) and BTG International Inc. (UK; LSE:BGC) | Aura Oncology Systems Inc.* | Licensing agreement for a patent portfolio in electronics and the life sciences | Agreement could lead to a bio-chip technology that could assist in the diagnosis of cancer and the development of new oncology drugs (2/5) |
Theratechnologies (Canada; TSE:TH) | Bioartificial Gel Technologies (Canada)* | Extended license agreement for Theratechnologies' extraction process and the applications of its platelet-derived growth factor cocktail | License agreement covers the in vivo use for therapeutic purposes in the areas of tissue engineering and wound healing (1/22) |
Transgenomic Inc. (TBIO) | Synthetic Genetics (division of Epoch Biosciences Inc.; EBIO) | Agreement for Synthetic Genetics to use its WAVE System for purification of DNA | Financial details were not disclosed (3/14) |
TranXenoGen Inc. (LSE:TXN) | Antitumor Research Products Inc.* | Worldwide licensing agreement for human antineoplastic urinary protein | The deal includes a small up-front payment and milestone payments to Antitumor Research Products, which may include a small issuance of TranXenoGen stock (3/5) |
Union Biometrica Inc.* | Clontech Laboratories Inc. (subsidiary of Becton, Dickinson & Co.; NYSE:BDX) | Licensing agreement for rights to Union's rights to COPAS Technology platform for automated drug testing in model organisms | Financial details were not available (1/11) |
Variagenics Inc. (VGNX) | Amgen Inc. (AMGN) | Agreement to apply Variagenics' Variagenic Impact Program to the development of an Amgen therapeutic | Financial details were not disclosed (1/4) |
Versicor Inc. (VERS) | Biosearch Italia SpA (Italy; Nuovo Mercato:BIO) | Expanded development partnership in anti-infective product leads | Expansion calls for formation of a research team; Biosearch will contribute additional selected microbial library compounds, fermentation extracts and high-throughput screening beyond the scope of the original agreement; Versicor will provide additional selected targets and assays for screening purposes (1/9) |
Xenerex Biosciences (subsidiary of Avanir Pharmaceuticals Inc.; AMEX:AVN) | IDEC Pharmaceuticals Corp. (IDEC) | Agreement giving Xenerex patent rights to U.S. Patent No. 5,958,765 for the generation of fully human monoclonal antibodies using human spleen cells grafted into severe combined immunodeficient mice | IDEC will receive a 5% ownership interest in Xenerex and royalties on sales resulting from use of the patent (2/13) |
Xenogen Corp.* | Chiron Corp. (CHIR) | Evaluation license agreement for access to Xenogen's real-time, in vivo imaging technologies | Chiron plans to evaluate Xenogen's technology for drug discovery applications in the treatment of cancer (1/16) |
Xenogen Corp.* | Onyx Pharmaceuticals Inc. (ONXX) | Six-month evaluation license for Xenogen's in vivo imaging technology | Onyx will use the technology to image bio-luminescent cancer cells in vivo for its virus research programs, and to image and study the biological activity of genetically altered viruses (3/8) |
XTL Biopharmaceuticals Ltd. (Israel; LSE:XTL) | Dyax Corp. (DYAX) | Collaborative agreement to discover, develop and commercialize fully human monoclonal antibodies to treat and/or prevent selected fungal infections and to treat selected cancers | The companies will share equally all development funding expenses and any outlicensing or other revenues (1/22) |
YM BioSciences Inc. (Canada)* | SR Pharma plc (UK; LSE: SPA) | Agreement to investigate the use of YMB's cancer antigen, IPS-21, in conjunction with SR Pharma's SRL172, a vaccine adjuvant | The agreement gives YMB the right to an exclusive license to develop SRL172 for use in combination with certain cancer antigens (1/31) |
Zyogen LLC* | Curis Inc. (CRIS) | Limited access agreement for Zyogen's transgenic zebrafish technology | Curis will use the technology, Z-tag, to accelerate its drug discovery program (2/21) |
|
Notes: |
|||
# This chart does not include agreements that involve agricultural product development. |
|||
* Private companies are indicated with an asterisk. ** Denotes the date the item ran in BioWorld International. |
|||
ND = Not disclosed, available or reported. |
|||
Unless otherwise noted, the trading symbols listed for public biotechnology companies are on the Nasdaq market. |
|||
AMEX = American Stock Exchange; CDNX = Canadian Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; SSE = Stockholm Stock Exchange; TSE = Toronto Stock Exchange |
|||
